SHARE
Peptide Therapeutics Market

Peptide Therapeutics Market Forecasts to 2028 – Global Analysis By Type (Innovative, Generic, Branded), Type of Molecule (Vasopressin, Somatostatin, Natriuretic), Route of Administration, Application, End User, and By Geography

4.2 (68 reviews)
Published: April 2022 ID: SMRC19307
4.2 (68 reviews)
Published: April 2022 ID: SMRC19307

This report covers the impact of COVID-19 on this global market

According to Stratistics MRC, the Global Peptide Therapeutics Market is accounted for $31.93 billion in 2021 and is expected to reach $56.52 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Peptides are the combination of two or more amino acid monomers linked by amide bonds. Researchers have demonstrated that peptide is distinguished from proteins on the basis of size. As a benchmark, molecules with less than 50 amino acids are considered as peptides. Peptides act by binding to specific cell surface receptors and mimics like receptor ligands and help in treatment of diseases by acting on the cell membrane. Peptides initially had applications only in diagnostics and hormonal therapy; however, with advances in technology, peptides are now being widely applied for therapeutic applications of cancer and chronic metabolic diseases.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases


The major factor driving the market growth is the increasing prevalence of cancer and metabolic disorders along with the technological advancements in peptide therapeutics. According to the World Health Organization (WHO), chronic diseases, such as cancer, cardiovascular diseases, and diabetes, are the leading causes of death and disability worldwide. Disease rates from chronic conditions are accelerating globally, advancing across every region and pervading all socioeconomic classes. In 2020, the contribution of chronic diseases was estimated to have caused 73% of all deaths and 60% of the global burden of diseases. Thus, the increasing incidence of chronic diseases accelerates the need for effective therapeutics, which in turn, is expected to drive the growth of the peptide therapeutics market.

Restraint:

Instability of peptides


One of the true drawbacks of peptide drugs is the increased proteolytic instability compared to not only small molecules but also monoclonal antibody therapeutics. The Fc fragment of monoclonal antibodies reshuffle the protein to cells and peptide-Fc conjugates may also be protected from enzymatic cleavage. Chemically, both the amide bond and the side-chains can be altered to render the resulting peptidomimetics resistant to proteolytic degradation. The serum stability assay provides a ready measure of peptide stability and was once considered the most significant secondary screening tool in drug development. Indeed, serum stability can provide a strong prediction of the all-important pharmacokinetic behavior of drugs. Chemical instability involves damage of the primary structure, covalent modification of the protein through bond formation or cleavage.

Opportunity:

Growing adoption of synthetic peptide drugs


Synthetic peptide drugs can be made to look like naturally occurring peptides and can be used to treat cancer and other serious illnesses. Synthetic peptides are chemically synthesized small polymers of amino acids. Synthetic peptides are used as affinity ligands. Several companies are capable of synthesizing peptides of up to 100 amino acid residues as a custom peptide synthesis service. Peptides are nowadays readily available by synthetic methodologies and can be produced in large quantities at low cost. They are obtained as defined and pure chemical entities, eliminating variability in biological results, and their use is devoid of infection and immunogenic risks. For instance, Hemmo has been supplying peptide products and custom peptide synthesis for more than 38 years, making it one of India's major makers of synthetic peptide drugs provider.

Threat:

Stringent regulatory challenges


The increasing interest of the pharmaceutical industry in peptide therapeutics has been a catalyst for the development of regulations in this area. Nevertheless, manufacturers and regulators continue to encounter scientific and regulatory challenges when dealing with peptides as active pharmaceutical ingredients in drug products. Being at the borderline between typical small molecules and large proteins, peptides have raised a series of regulatory challenges. Since there are various peptide conjugate candidates that contain peptides in combination with small molecules, the regulatory aspect for peptide is still evolving. The FDA takes into account the history and manufacturing aspect of the candidate molecule to decide its regulatory pathway Example whether BLA would be submitted or NDA needs to be applied. Disparities in interpretation and application of existing International Council for Harmonisation (ICH) and United States Food and Drug Administration (FDA) regulatory guidances have resulted in challenges, inconsistencies, and confusion for both regulators and drug developers.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to have a lucrative growth. Peptides offer favorable prospects in targeted drug delivery for cancer due to their high specificity, discernment, small sizes, ease of modification, and high biocompatibility. The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment. Moreover, the high prevalence of cancer cases globally is expected to play a vital role in the growth of the studied segment over the forecast period. Furthermore, rising awareness among patients and healthcare professionals regarding the adverse effects of chemotherapy and radiation therapy is a major factor for the growing focus on alternative therapeutics such as peptide-based drugs.

The oral segment is expected to have the highest CAGR during the forecast period

The oral segment is anticipated to witness the fastest CAGR growth during the forecast period.  Due to a decrease in non-peptide chemical medications accessible in the market, sales of peptide therapeutic companies are currently rising. As peptides are a common component of food, both, the stomach and intestines contain a plethora of enzymes that can break them down, and most peptide-based drugs do not survive the gastrointestinal tract.  The peptides generics market is expected to develop as the patent cliff rises. Because pharma businesses are shifting their focus to better potential in the peptide therapies sector, CMOs that provide end-to-end services to biotech pharmaceutical companies are rising. For instance, Heinis's Group is currently using a novel technology to develop oral peptide drugs that act directly on gastrointestinal targets, bypassing the bloodstream. Oral peptide drugs will play a crucial role in the treatment of a wide range of disorders.

Region with highest share:

North America is projected to hold the largest market share during the forecast period. North America is expected to dominate the overall market throughout the forecast period. The market growth is due to factors such as a rise in awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the growing biotechnology industry. A properly established biopharmaceutical and pharmaceutical industry in this region is a major factor responsible for growth. In the North American region, the United States holds the largest market share due to factors such as the increasing number of research programs in the medical industry and the growing number of diseases in the country, which is anticipated to stimulate the demand in this region. Owing to the increasing burden of cancer, the demand for peptide therapeutics is expected to grow. Hence, given the aforementioned factors, the peptide therapeutics market is expected to witness significant growth in North America over the forecast period.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. Vast patient pool, increasing healthcare expenditure and demand for newer advanced therapies are key factors likely to boost peptide therapeutics market in Asia Pacific. Government funding for the use of peptides in the production of COVID-19 vaccines is expected to provide a potential incentive for the adoption of the peptides, potentially driving the growth of the APAC peptide therapeutics market.

Key players in the market

Some of the key players profiled in the Peptide Therapeutics Market include Bachem Holding AG, Bristol-Myers Squibb(BMS), Eli Lilly and Company, GlaxoSmithKline (GSK), ISSAR Pharmaceuticals, Lonza Inc, Merck & Co, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Sanofi, Takeda Pharmaceutical Company Limited, and Xenetic Biosciences, Inc.

Key Developments:

In May 2021, ISSAR Pharmaceuticals took the decision to license out its peptide-based new chemical entities (NCEs) with pre-IND filing and the United States Patent for various unmet healthcare needs of the population, making it affordable and accessible for better health outcomes.

In July 2019, Xenetic Biosciences, Inc. completed acquisition of the novel CAR T (“Chimeric Antigen Receptor T Cell”) platform technology, called “XCART,” designed to use screening technique to identify peptide ligands that bind specifically to the unique B-cell receptor of malignant tumor cells.
 
Synthesis Technologies Covered:
• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology
 
Route of Administrations Covered:
• Pulmonary
• Parenteral
• Oral
• Mucosal
• Injection
• Other Route of Administrations
 
Types Covered:
• Innovative
• Generic
• Branded
 
Type of Manufacturers Covered:
• Outsourced
• In-house
• Contract Manufacturing Organizations (CMOs)
 
Type of Molecules Covered:
• Vasopressin
• Somatostatin
• Natriuretic
• Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
• Insulins
• Immunopeptide
• Glucagon and Analogs
• Calcitonin
 
Applications Covered:
• Acromegaly
• Anti-infection
• Cancer
• Cardiovascular Disorder
• Central Nervous System (Copaxone (Glatiramer))
• Dermatology
• Gastro-Intestinal Infection (GIT)
• Hematological Disorders
• Infection
• Metabolic
• Pain
• Renal
• Respiratory
• Other Applications
 
End Users Covered:
• Pharmaceutical and Biotechnology Industries
• Hospitals
• Contract Research Organization
• Academic and Research Institutes


Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan       
o China       
o India       
o Australia 
o New Zealand
o South Korea
o Rest of Asia Pacific   
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary        
          
2 Preface         

 2.1 Abstract        
 2.2 Stake Holders       
 2.3 Research Scope       
 2.4 Research Methodology      
  2.4.1 Data Mining      
  2.4.2 Data Analysis      
  2.4.3 Data Validation      
  2.4.4 Research Approach      
 2.5 Research Sources       
  2.5.1 Primary Research Sources     
  2.5.2 Secondary Research Sources     
  2.5.3 Assumptions      
          
3 Market Trend Analysis       
 3.1 Introduction       
 3.2 Drivers        
 3.3 Restraints       
 3.4 Opportunities       
 3.5 Threats        
 3.6 Technology Analysis      
 3.7 Application Analysis      
 3.8 End User Analysis        
 3.9 Emerging Markets       
 3.10 Impact of Covid-19       
          
4 Porters Five Force Analysis       
 4.1 Bargaining power of suppliers      
 4.2 Bargaining power of buyers      
 4.3 Threat of substitutes      
 4.4 Threat of new entrants      
 4.5 Competitive rivalry       
          
5 Global Peptide Therapeutics Market, By Synthesis Technology   
 5.1 Introduction       
 5.2 Solid Phase Peptide Synthesis (SPPS)     
 5.3 Liquid Phase Peptide Synthesis (LPPS)     
 5.4 Hybrid Technology       
          
6 Global Peptide Therapeutics Market, By Route of Administration   
 6.1 Introduction       
 6.2 Pulmonary       
 6.3 Parenteral       
 6.4 Oral        
 6.5 Mucosal        
 6.6 Injection        
 6.7 Other Route of Administrations     
  6.7.1 Intradermal      
  6.7.2 Nasal       
          
7 Global Peptide Therapeutics Market, By Type     
 7.1 Introduction       
 7.2 Innovative       
 7.3 Generic        
 7.4 Branded        
          
8 Global Peptide Therapeutics Market, By Type of Manufacturer   
 8.1 Introduction       
 8.2 Outsourced       
 8.3 In-house        
 8.4 Contract Manufacturing Organizations (CMOs)    
          
9 Global Peptide Therapeutics Market, By Type of Molecule    
 9.1 Introduction       
 9.2 Vasopressin       
 9.3 Somatostatin       
 9.4 Natriuretic       
 9.5 Luteinizing Hormone (LH)-Releasing Hormone (LHRH)   
 9.6 Insulins        
 9.7 Immunopeptide       
 9.8 Glucagon and Analogs      
 9.9 Calcitonin       
          
10 Global Peptide Therapeutics Market, By Application    
 10.1 Introduction       
 10.2 Acromegaly       
 10.3 Anti-infection       
 10.4 Cancer        
  10.4.1 Lupron/ Enantone/ Eligard (Leuprorelin)    
  10.4.2 Velcade (Bortezomib)     
  10.4.3 Zoladex (Goserelin)      
 10.5 Cardiovascular Disorder      
  10.5.1 Angiomax (Bivalirudin)     
  10.5.2 Integrilin (Eptifibatide)     
 10.6 Central Nervous System (Copaxone (Glatiramer))    
 10.7 Dermatology       
 10.8 Gastro-Intestinal Infection (GIT)     
  10.8.1 Gattex (Teduglutide)     
  10.8.2 Linzess (Linaclotide)     
 10.9 Hematological Disorders      
  10.9.1 Firazyr (Icatibant)      
  10.9.2 Kalbitor (Ecallantide)     
 10.10 Infection        
  10.10.1 Incivek (Telaprevir)      
  10.10.2 Victrelis (Boceprevir)     
 10.11 Metabolic       
  10.11.1 Victoza (Liraglutide)     
  10.11.2 Byetta (Exenatide)      
 10.12 Pain        
 10.13 Renal        
 10.14 Respiratory       
 10.15 Other Applications       
  10.15.1 Osteoporosis      
  10.15.2 Allergy/Immunological     
          
11 Global Peptide Therapeutics Market, By End User     
 11.1 Introduction       
 11.2 Pharmaceutical and Biotechnology Industries    
 11.3 Hospitals        
 11.4 Contract Research Organization     
 11.5 Academic and Research Institutes     
          
12 Global Peptide Therapeutics Market, By Geography    
 12.1 Introduction       
 12.2 North America       
  12.2.1 US       
  12.2.2 Canada       
  12.2.3 Mexico       
 12.3 Europe        
  12.3.1 Germany       
  12.3.2 UK       
  12.3.3 Italy       
  12.3.4 France       
  12.3.5 Spain       
  12.3.6 Rest of Europe      
 12.4 Asia Pacific       
  12.4.1 Japan       
  12.4.2 China       
  12.4.3 India       
  12.4.4 Australia       
  12.4.5 New Zealand      
  12.4.6 South Korea      
  12.4.7 Rest of Asia Pacific      
 12.5 South America       
  12.5.1 Argentina      
  12.5.2 Brazil       
  12.5.3 Chile       
  12.5.4 Rest of South America     
 12.6 Middle East & Africa      
  12.6.1 Saudi Arabia      
  12.6.2 UAE       
  12.6.3 Qatar       
  12.6.4 South Africa      
  12.6.5 Rest of Middle East & Africa     
          
13 Key Developments        
 13.1 Agreements, Partnerships, Collaborations and Joint Ventures   
 13.2 Acquisitions & Mergers      
 13.3 New Product Launch      
 13.4 Expansions       
 13.5 Other Key Strategies      
          
14 Company Profiling        
 14.1 Amgen Inc       
 14.2 AstraZeneca PLC       
 14.3 Bachem Holding AG       
 14.4 Bristol-Myers Squibb(BMS)      
 14.5 Eli Lilly and Company      
 14.6 GlaxoSmithKline (GSK)      
 14.7 ISSAR Pharmaceuticals      
 14.8 Lonza Inc        
 14.9 Merck & Co       
 14.10 Novartis AG       
 14.11 Novo Nordisk A/S       
 14.12 Pfizer Inc        
 14.13 Sanofi        
 14.14 Takeda Pharmaceutical Company Limited    
 14.15 Xenetic Biosciences, Inc      


List of Tables         
1 Global Peptide Therapeutics Market Outlook, By Region (2020-2028) ($MN)  
2 Global Peptide Therapeutics Market Outlook, By Synthesis Technology (2020-2028) ($MN) 
3 Global Peptide Therapeutics Market Outlook, By Solid Phase Peptide Synthesis (SPPS) (2020-2028) ($MN)
4 Global Peptide Therapeutics Market Outlook, By Liquid Phase Peptide Synthesis (LPPS) (2020-2028) ($MN)
5 Global Peptide Therapeutics Market Outlook, By Hybrid Technology (2020-2028) ($MN) 
6 Global Peptide Therapeutics Market Outlook, By Route of Administration (2020-2028) ($MN) 
7 Global Peptide Therapeutics Market Outlook, By Pulmonary (2020-2028) ($MN)  
8 Global Peptide Therapeutics Market Outlook, By Parenteral (2020-2028) ($MN)  
9 Global Peptide Therapeutics Market Outlook, By Oral (2020-2028) ($MN)   
10 Global Peptide Therapeutics Market Outlook, By Mucosal (2020-2028) ($MN)  
11 Global Peptide Therapeutics Market Outlook, By Injection (2020-2028) ($MN)  
12 Global Peptide Therapeutics Market Outlook, By Other Route of Administrations (2020-2028) ($MN)
13 Global Peptide Therapeutics Market Outlook, By Intradermal (2020-2028) ($MN)  
14 Global Peptide Therapeutics Market Outlook, By Nasal (2020-2028) ($MN)  
15 Global Peptide Therapeutics Market Outlook, By Type (2020-2028) ($MN)  
16 Global Peptide Therapeutics Market Outlook, By Innovative (2020-2028) ($MN)  
17 Global Peptide Therapeutics Market Outlook, By Generic (2020-2028) ($MN)  
18 Global Peptide Therapeutics Market Outlook, By Branded (2020-2028) ($MN)  
19 Global Peptide Therapeutics Market Outlook, By Type of Manufacturer (2020-2028) ($MN) 
20 Global Peptide Therapeutics Market Outlook, By Outsourced (2020-2028) ($MN)  
21 Global Peptide Therapeutics Market Outlook, By In-house (2020-2028) ($MN)  
22 Global Peptide Therapeutics Market Outlook, By Contract Manufacturing Organizations (CMOs) (2020-2028) ($MN)
23 Global Peptide Therapeutics Market Outlook, By Type of Molecule (2020-2028) ($MN) 
24 Global Peptide Therapeutics Market Outlook, By Vasopressin (2020-2028) ($MN)  
25 Global Peptide Therapeutics Market Outlook, By Somatostatin (2020-2028) ($MN)  
26 Global Peptide Therapeutics Market Outlook, By Natriuretic (2020-2028) ($MN)  
27 Global Peptide Therapeutics Market Outlook, By Luteinizing Hormone (LH)-Releasing Hormone (LHRH) (2020-2028) ($MN)
28 Global Peptide Therapeutics Market Outlook, By Insulins (2020-2028) ($MN)  
29 Global Peptide Therapeutics Market Outlook, By Immunopeptide (2020-2028) ($MN) 
30 Global Peptide Therapeutics Market Outlook, By Glucagon and Analogs (2020-2028) ($MN) 
31 Global Peptide Therapeutics Market Outlook, By Calcitonin (2020-2028) ($MN)  
32 Global Peptide Therapeutics Market Outlook, By Application (2020-2028) ($MN)  
33 Global Peptide Therapeutics Market Outlook, By Acromegaly (2020-2028) ($MN)  
34 Global Peptide Therapeutics Market Outlook, By Anti-infection (2020-2028) ($MN)  
35 Global Peptide Therapeutics Market Outlook, By Cancer (2020-2028) ($MN)  
36 Global Peptide Therapeutics Market Outlook, By Lupron/ Enantone/ Eligard (Leuprorelin) (2020-2028) ($MN)
37 Global Peptide Therapeutics Market Outlook, By Velcade (Bortezomib) (2020-2028) ($MN) 
38 Global Peptide Therapeutics Market Outlook, By Zoladex (Goserelin) (2020-2028) ($MN) 
39 Global Peptide Therapeutics Market Outlook, By Cardiovascular Disorder (2020-2028) ($MN) 
40 Global Peptide Therapeutics Market Outlook, By Angiomax (Bivalirudin) (2020-2028) ($MN) 
41 Global Peptide Therapeutics Market Outlook, By Integrilin (Eptifibatide) (2020-2028) ($MN) 
42 Global Peptide Therapeutics Market Outlook, By Central Nervous System (Copaxone (Glatiramer)) (2020-2028) ($MN)
43 Global Peptide Therapeutics Market Outlook, By Dermatology (2020-2028) ($MN)  
44 Global Peptide Therapeutics Market Outlook, By Gastro-Intestinal Infection (GIT) (2020-2028) ($MN)
45 Global Peptide Therapeutics Market Outlook, By Gattex (Teduglutide) (2020-2028) ($MN) 
46 Global Peptide Therapeutics Market Outlook, By Linzess (Linaclotide) (2020-2028) ($MN) 
47 Global Peptide Therapeutics Market Outlook, By Hematological Disorders (2020-2028) ($MN) 
48 Global Peptide Therapeutics Market Outlook, By Firazyr (Icatibant) (2020-2028) ($MN) 
49 Global Peptide Therapeutics Market Outlook, By Kalbitor (Ecallantide) (2020-2028) ($MN) 
50 Global Peptide Therapeutics Market Outlook, By Infection (2020-2028) ($MN)  
51 Global Peptide Therapeutics Market Outlook, By Incivek (Telaprevir) (2020-2028) ($MN) 
52 Global Peptide Therapeutics Market Outlook, By Victrelis (Boceprevir) (2020-2028) ($MN)  
53 Global Peptide Therapeutics Market Outlook, By Metabolic (2020-2028) ($MN)  
54 Global Peptide Therapeutics Market Outlook, By Victoza (Liraglutide) (2020-2028) ($MN) 
55 Global Peptide Therapeutics Market Outlook, By Byetta (Exenatide) (2020-2028) ($MN) 
56 Global Peptide Therapeutics Market Outlook, By Pain (2020-2028) ($MN)   
57 Global Peptide Therapeutics Market Outlook, By Renal (2020-2028) ($MN)  
58 Global Peptide Therapeutics Market Outlook, By Respiratory (2020-2028) ($MN)  
59 Global Peptide Therapeutics Market Outlook, By Other Applications (2020-2028) ($MN) 
60 Global Peptide Therapeutics Market Outlook, By Osteoporosis (2020-2028) ($MN)  
61 Global Peptide Therapeutics Market Outlook, By Allergy/Immunological (2020-2028) ($MN) 
62 Global Peptide Therapeutics Market Outlook, By End User (2020-2028) ($MN)  
63 Global Peptide Therapeutics Market Outlook, By Pharmaceutical and Biotechnology Industries (2020-2028) ($MN)
64 Global Peptide Therapeutics Market Outlook, By Hospitals (2020-2028) ($MN)  
65 Global Peptide Therapeutics Market Outlook, By Contract Research Organization (2020-2028) ($MN)
66 Global Peptide Therapeutics Market Outlook, By Academic and Research Institutes (2020-2028) ($MN)
          
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Allows one person to have access to the ordered product.The ordered product cannot be distributed to anyone else.
Allows the ordered product to be shared among a maximum of 5 people within your organisation.
Allows the product to be shared among all employees of your organisation at one particular location.
Allows the product to be shared among all employees of your organisation regardless of their geographical location.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials